GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion

Consider TIPS in Treating Portal Hypertension

Time to Rethink TIPS

Advanced by compelling evidence, earlier transjugular intrahepatic portosystemic shunt (TIPS) is helping physicians increase survival in high-risk liver disease patients.

Higher transplant-free survival for recurrent ascites at one year*,1
 

93% TIPS
vs. 52%
large-volume paracenteses (LVP)
+ albumin(A) (P = .003)

Higher survival in Child-Pugh C patients with acute variceal bleeding (AVB) at one year†,2

78% TIPS
vs. 53%
pharmacotherapy+endoscopic
band ligation (EBL) (P = .002)

READ ABOUT 20 YEARS OF EXPERTISE WITH TIPS

READ ABOUT EARLIER TIPS FOR ASCITES AND VARICEAL BLEEDING

Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly

eIFU Symbol

Footnotes & References

* Early TIPS (n = 29) compared to large-volume paracenteses and albumin infusion (LVP+A) (n = 33).

† Early TIPS (n = 66) compared to pharmacotherapy+endoscopic band ligation (EBL) (n = 605). Child-Pugh C patients with scores < 14.

  1. Bureau C, Thabut D, Oberti D, et al.  Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites.  Gastroenterology 2017;152(1):157-163.  http://www.sciencedirect.com/science/article/pii/S0016508516351101
  2.  Hernández-Gea V, Procopet B, Giráldez Á, et al; International Variceal Bleeding Observational Study Group and Baveno Cooperation.  Preemptive-TIPS improves outcome in high-risk variceal bleeding: an observational study.  Hepatology 2019;69(1):282-293.  https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.30182

For the approved indications of the GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion see Instructions for Use. All products are CE-certified under Regulation (EU) 2017/745 (hereinafter the “MDR”). But please note that GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion that have already been placed on the market before do not require re-certification, as the MDR provides for an extended transition period (Article 120 of the MDR). Those products continue to hold existing and valid CE-certification under EU directive 93/42/EEC and can be used further in accordance with the label, either until product expiration or May 2025.

22730084-EN

Residents of some states have the right to opt-out of the “sharing” or “selling” of their personal information. Gore does not "sell" the personal information of website users. Gore may "share" the personal information of website users, as standard advertising practice meant to offer you a more personalized service.

If you want to opt-out from Gore “sharing” your personal information, click on Opt-Out of Sharing to turn off the targeting cookies that we share with our advertising partners in order to provide you with personalized information. Disabling sharing will stop the use of cookies to targeted advertising but you may still see generic Gore ads.

Please note that your exercising of the rights outlined will have no adverse effect on the price and quality of our goods or services.

Opt-Out of Sharing

You Have Successfully Opted Out of the Sharing of Your Personal Information

Please note that if you clear your cookies and then use another device or browser, etc. your opt-out status is not transferred to the new device or browser.